{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:08:17Z","timestamp":1787242097086,"version":"build-2736575974"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T00:00:00Z","timestamp":1493856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0177057","type":"journal-article","created":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T14:17:11Z","timestamp":1493907431000},"page":"e0177057","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":23,"title":["Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2197-0757","authenticated-orcid":true,"given":"Naoki","family":"Iwamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sosuke","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayuko","family":"Takatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimasa","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Umeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Horai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ya","family":"Kawashiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Aramaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Ichinose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuko","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Origuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukitaka","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,5,4]]},"reference":[{"issue":"9746","key":"ref1","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"DL Scott","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"ref2","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force","volume":"69","author":"JS Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"9865","key":"ref3","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"GR Burmester","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"ref4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"R Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"ref5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","article-title":"Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial","volume":"159","author":"J Kremer","year":"2013","journal-title":"Ann Intern Med"},{"issue":"25","key":"ref6","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"EB Lee","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"ref7","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","article-title":"Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study","volume":"65","author":"D van der Heijde","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"6","key":"ref8","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"RF van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"ref9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/acr.22783","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"68","author":"JA Singh","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref10","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","author":"JS Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"ref11","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"D Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"ref12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/ard.2006.054205","article-title":"Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values","volume":"66","author":"E Inoue","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"ref13","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s00296-015-3291-4","article-title":"Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials","volume":"35","author":"YH Lee","year":"2015","journal-title":"Rheumatol Int"},{"issue":"11","key":"ref14","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"P Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"ref15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/art.22331","article-title":"Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study","volume":"56","author":"KL Hyrich","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"4","key":"ref16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/rheumatology\/ken034","article-title":"Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register","volume":"47","author":"JA Karlsson","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"ref17","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/ard.2007.085787","article-title":"Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies","volume":"68","author":"E Keystone","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"ref18","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1136\/annrheumdis-2013-203993","article-title":"Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study","volume":"74","author":"P Emery","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"ref19","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3109\/s10165-011-0516-6","article-title":"Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study)","volume":"22","author":"T Takeuchi","year":"2012","journal-title":"Mod Rheumatol"},{"issue":"10","key":"ref20","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"KL Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"ref21","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1002\/art.34329","article-title":"The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4+ T cells","volume":"64","author":"K Maeshima","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"8","key":"ref22","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1089\/1079990041689665","article-title":"Induction and regulation of IFNs during viral infections","volume":"24","author":"L Malmgaard","year":"2004","journal-title":"J Interferon Cytokine Res"},{"issue":"6","key":"ref23","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1189\/jlb.0504282","article-title":"The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing","volume":"76","author":"M Conklyn","year":"2004","journal-title":"J Leukoc Biol"},{"issue":"9","key":"ref24","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1097\/01.tp.0000177643.05739.cd","article-title":"Effects of JAK3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts","volume":"80","author":"R Paniagua","year":"2005","journal-title":"Transplantation"},{"issue":"5","key":"ref25","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","article-title":"Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme","volume":"75","author":"JR Curtis","year":"2016","journal-title":"Ann Rheum Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0177057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T02:13:28Z","timestamp":1588990408000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0177057"}},"subtitle":[],"editor":[{"given":"Masataka","family":"Kuwana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,5,4]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0177057","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,4]]}}}